Network Meta-Analyses—Better Than Nothing?
A partir d'une revue systématique de la littérature publiée jusqu'en juillet 2023 (5 essais, 2 385 patients), cette méta-analyse évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité des anti-PD-1/PD-L1 en traitement néoadjuvant uniquement ou en traitement néoadjuvant puis adjuvant chez les patients atteints d'un cancer du poumon non à petites cellules résécable
In the last few years, immune checkpoint inhibitors have shown positive results in the treatment of patients with resectable non–small cell lung cancer (NSCLC), while until recently the only systemic treatment that had demonstrated a significant benefit compared with surgery alone was chemotherapy, administered as adjuvant treatment (more often) or as neoadjuvant therapy (less commonly). In detail, some recent trials evaluated the use of adjuvant immunotherapy: 1 trial evaluated the simple addition of immunotherapy to preoperative treatment without further postoperative systemic therapies, while other studies tested as experimental treatment the addition of immunotherapy both before and after surgery. Unfortunately, the latter design does not allow us to understand the benefit, if any, associated with the postoperative administration of immunotherapy to patients who have already received the same drug as part of the neoadjuvant treatment.
JAMA Network Open 2024